In vivo toxicity of foscarnet and zidovudine given alone or in combination

Toxicology and Applied Pharmacology

Volumn 139, Issue 2, 1996, Pages 324-332

  Omar, Rabeea F ^b   Gourde, Pierrette ^b   Désormeaux, André ^b   Tremblay, Michel ^b   Beauchamp, Denis ^b   Bergeron, Michel G ^a  

^a LAVAL UNIVERSITY   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

FOSCARNET; HEMOGLOBIN; ZIDOVUDINE;

ANIMAL EXPERIMENT; ARTICLE; BLOOD TOXICITY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DOSE RESPONSE; ELECTRON MICROSCOPY; ERYTHROCYTE COUNT; FEMALE; HEMATOCRIT; HISTOPATHOLOGY; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NEPHROTOXICITY; NONHUMAN; THROMBOCYTE COUNT; UREA NITROGEN BLOOD LEVEL;

ANIMALIA;

EID: 0030220006     PISSN: 0041008X     EISSN: None     Source Type: Journal    
DOI: 10.1006/taap.1996.0172     Document Type: Article

References (32)

1. Aweeka, F. T., Gambertoglio, J. G., van der Horst, C., Raasch, R., and Jacobson, M. A. (1992). Pharmacokinetics of concomitantly administered foscarnet and zidovudine for treatment of human immunodeficiency virus infection (AIDS clinical trial group protocol 053). Antimicrob. Agents Chemother. 36, 1773-1778.
2. Blum, M. R., Lao, S. H. T., Good, S. S., and deMiranda, P. (1988). Pharmacokinetics and bioavailability of zidovudine in humans. Am. J. Med. 85 (Suppl. 2A), 189-194.
3. Chrisp, P., and Clissold, P. (1991). Foscarnet. A review of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with cytomegalovirus retinitis. Drugs 41, 104-129.
4. Collins, J. M., and Unadkat, J. D. (1989). Clinical pharmacokinetics of zidovudine: An overview of current data. Clin. Pharmacokinet. 17, 1-9.
5. Deray, G., Martinez, F., Katlama, C., Levaltier, B., Beaufils, H., Danis, M., Rozenheim, M., Baumelou, A., Dohin, E., Gentilini, M., and Jacobs, C. (1989). Foscarnet nephrotoxicity: Mechanism, incidence and prevention. Am. J. Nephrol. 9, 316-321.
6. Dournon, E., Matheron, S., Rozenbaum, W., Gharakhanian, S., Michon, C., Girard, P. M., Perronne, C., Salmon, D., De Truchis, P., Leport, C., Bouvet, E., Dazza, M. C., Levacher, M., and Regnier, B. (1988). Effects of zidovudine in 365 consecutive patients with AIDS or AIDS-related complex. Lancet 2, 1297-1302.
7. Eriksson, B., and Schinazi, R. F. (1989). Combination of 3′-azido-3′-deoxythymidine (zidovudine) and phosphonoformate (foscarnet) against human immunodeficiency virus type I and cytomegalovirus replication in vitro. Antimicrob. Agents Chemoher. 33, 663-668.
8. Fanning, M. M., Read, S. E., Benson, M., Vas, S., Rachlis, A., Kozousek, V., Mortimer, C., Harvey, P., Schwartz, C., Chew, E., Brunton, J., Matlow, A., Salit, I., Vellend, H., and Walmsley, S. (1990). Foscarnet therapy of cytomegalovirus retinitis in AIDS. J. Acquir. Immune Defic. Syndr. 3, 472-479.
9. Farthing, C., Anderson, M. G., Ellis, M. E., Gazzard, B. G., and Chanas, A. C. (1987). Treatment of cytomegalovirus pneumonitis with foscarnet (trisodium phosphonoformate) in patients with AIDS. J. Med. Virol. 22, 157-162.
10. Fischl, M. A., Richman, D. D., Causey, D. M., Grieco, M. H., Bryson, Y., Mildvan, D., Laskin, O. L., Groopman, J. E., Volberding, P. A., Schooley, R. T., Jackson, G. G., Durack, D. T., Andrews, J. C., Nusinoff-Lehrman, S., Barry, D. W., and the AZT Collaborative Working Group. (1989). Prolonged zidovudine therapy in patients with AIDS and advanced AIDS-related complex. J. Am. Med. Assoc. 262, 2405-2410.
11. Fischl, M. A., Stanley, K., Collier, A., Arduino, J. M., Stein, D. S., Feinberg, J. E., Allen, J. D., Goldsmith, J. C., and Powdely, W. G. (1995). Combination and monotherapy with zidovudine and zalcitabline in patients with advanced HIV disease. Ann. Intern. Med. 122, 24-32.
12. Fletcher, C. V., Collier, A. C., Rhame, F. S., Bennett, D., Para, M. F., Beatty, C. C., Jones, C. E., and Balfour, H. H., Jr. (1994). Foscarnet for suppression of human immunodeficiency virus replication. Antimicrob. Agents Chemother. 38, 604-607.
13. Gelmon, K., Montaner, J. S. G., Fanning, M., Smith, J. R. M., Falutz, J., Tsoukas, C., Gill, J., Wells, G., O'Shaughnessy, M., Wainberg, M., and Ruedy, J. (1989). Nature, time course and dose dependence of zidovudine-related side effects: Results from the multicenter Canadian azidothymidine trial. AIDS 3, 555-561.
14. Good, S. S., Durack, D. T., and deMiranda, P. (1986). Biotransformation in various species and in humans of 3′-azido-3′-deoxythymidine, a potential agent for treatment of AIDS. Fed. Proc. 45, 444.
15. Hammer, S. M., Kessler, H. A., and Saag, M. S. (1994). Issues in combination antiretroviral therapy: A review. J. Acquir. Immune Defic. Syndr. 7 (Suppl. 2), S24-S37.
16. Jabs, D. A., Davis, M. D., Meinert, C. L., Mowery, R., et al. (1995). Morbidity and toxic effects associated with ganciclovir or foscarnet therapy in a randomized cytomegalovirus retinitis trial. Studies of ocular complications of AIDS Research Group, in collaboration with the AIDS Clinical Trial Group. Arch. Intern. Med. 155, 65-74.
17. Jacobson, M. A. (1992). Review of the toxicities of foscarnet. J. AIDS 5 (Suppl. 1), S11-S17.
18. Jacobson, M. A., Crowe, S., Levy, J., Aweeka, F., Gambertoglio, J., McManus, N., and Mills, J. (1988). Effect of foscarnet therapy on infection with human immunodeficiency virus in patients with AIDS. J. Infect. Dis. 158, 862-865.
19. Jacobson, M. A., O'Donnel, J. J., and Mills, J. (1989). Foscarnet treatment of cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome. Antimicrob. Agents Chemother. 33, 736-741.
20. Koshida, R., Vrang, L., Gilljam, G., Harmenberg, J., Öberg, B., and Wahren, B. (1989). Inhibition of human immunodeficiency virus in vitro by combination of 3′-azido-3′-Deoxythymidine and Foscarnet. Antimicrob. Agents Chemother. 33, 778-780.
21. Larder, B. A., Kemp, S. D., and Harrigan, P. R. (1995). Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 269, 696-699.
22. Matthews, S. J., Cersosimo, R. J., and Spivack, M. L. (1991). Zidovudine and other reverse transcriptase inhibitors in the management of human immunodeficiency virus-related disease. Pharmacotherapy 11, 419-449.
23. Nyberg, G., Svalander, C., Blohme, I., and Persson, H. (1989). Tubulointerstitial nephritis caused by the antiviral agent foscarnet. Transplant Int. 2, 223-227.
24. Öberg, B. (1989). Antiviral effects of phosphonoformate. Pharmacol. Ther. 40, 213-285.
25. Omar, R. F., Dusserre, N., Désormeaux, A., Poulin, L., Tremblay, M., Beauchamp, D., and Bergeron, M. G. (1995). Liposomal encapsulation of foscarnet protects against hypocalcemia induced by free foscarnet. Antimicrob. Agents Chemother. 39, 1973-1978.
26. Palestine, A. G., Polis, M. A., De Smet, M. D., Baird, B. F., Falloon, J., Kovacs, J. A., Davey, R. T., Zurlo, J. J., Zunich, K. M., Davis, M., Hubbard, L., Brothers, R., Ferris, F. L., Chew, E., Davis, J. L., Rubin, B. I., Mellow, S. D., Metcalf, J. A., Manischewitz, J., Minor, J. R., Nussenblatt, R. B., Masur, H., and Lane, C. (1991). A randomized controlled trial of foscarnet in the treatment of cytomegalovirus retinitis in patients with AIDS. Ann. Intern. Med. 115, 665-673.
27. Palmer, S., Rasmussen, H., Harmenberg, J., and Cox, S. (1996). Intracellular metabolism of 3′-azido-3′-deoxythymidine in the presence of ganciclovir or foscarnet. Antiviral Chem. Chemother. 7, 14-20.
28. Reddy, M. M., Grieco, M. H., McKinley, G. F., Causey, D. M., van der Horst, C. M., Parenti, D. M., Hooton, T. M., Davis, R. B., and Jacobson, M. A. (1992). Effect of foscarnet therapy on human immunodeficiency virus p24 antigen levels in AIDS patients with cytomegalovirus retinitis. J. Infect. Dis. 166, 607-610.
29. Richman, D. D., Fischl, M. A., Grieco, M. H., Grieco, M. H., Gottlieb, M. S., Volberding, P. A., Laskin, O. L., Leedom, J. M., Groopman, J. E., Mildvan, D., Hirsch, M. S., Jackson, G. C., Durack, D. T., Nusinoff-Lehrman, S., and the AZT Collaborative Working Group. (1987). The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. N. Engl. J. Med. 317, 192-197.
30. Sandström, E. G., Kaplan, J. C., Byington, R. E., and Hirsch, M. S. (1985). Inhibition of human T-cell lymphotropic virus type III in vitro by phosphonoformate. Lancet 1, 1480-1482.
31. Shafer, R. W., Iversen, K. N., Winters, M. A., Aguiniga, E., Katzenstein, D., Merigan, T. C., and The AIDS Clinical Trial Group 143 Virology Team. (1995). Drug resistance and heterogenous long-term virologic responses of human immunodeficiency virus type 1-infected subjects to zidovudine and didanosine combination therapy. J. Infect. Dis. 172, 70-78.
32. Thompson, M. B., Dunnick, J. K., Sutphin, M. E., Giles, H. D., Irwin, R. D., and Prejean, J. D. (1991). Hematologic toxicity of AZT and ddC administered as single agents and in combination to rats and mice. Fundam. Appl. Toxicol. 17, 159-176.